PTGER4
ENSG00000171522
Target class
GPCR
Chromosome
5
Approved drugs
1
Clinical candidates (approved and in development)
4
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Other names
- EP4
- Target name
- PTGER4
- Gene name
- Prostaglandin E receptor 4
- Gene symbol
- PTGER4
- Protein name
- Prostaglandin E2 receptor EP4 subtype (PGE receptor EP4 subtype) (PGE2 receptor EP4 subtype) (Prostanoid EP4 receptor)
- Gene biotype
- Protein coding
- Gene family
- Prostaglandin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 40
- Highest tissue expression
- 24.39
- Tissue specificity (Gini)
- 0.485
- Tissue specificity (tau)
- 0.752
- KEGG gene identifiers
- hsa:5734
- Protein interaction confidence
- 0.846087
- Protein interaction partners
- 23
- R-HSA-391908
- R-HSA-418555
- End position
- 40693735
- Start position
- 40679915
- Chromosome
- 5
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.752133
- Expression inequality (Gini)
- 0.484776
Expression in transcripts per million
- Lung
- 24.39
- Colon - Transverse
- 17.81
- Small Intestine - Terminal Ileum
- 16.93
- Adipose - Visceral (Omentum)
- 16.8
- Colon - Sigmoid
- 16.19
Expression in transcripts per million
- Lung24.39
- Colon - Transverse17.81
- Small Intestine - Terminal Ileum16.93
- Adipose - Visceral (Omentum)16.8
- Colon - Sigmoid16.19
- Adipose - Subcutaneous14.97
- Spleen14.54
- Fallopian Tube13.87
- Pancreas12.57
- Artery - Tibial11.85
- Nerve - Tibial11.83
- Breast - Mammary Tissue11.24
- Bladder10.3
- Kidney - Medulla10.04
- Stomach8.84
- Whole Blood8.79
- Kidney - Cortex7.43
- Artery - Coronary7.31
- Cervix - Endocervix7.14
- Thyroid6.67
- Esophagus - Gastroesophageal Junction6.53
- Skin - Not Sun Exposed (Suprapubic)6.24
- Skin - Sun Exposed (Lower leg)6.08
- Esophagus - Muscularis5.84
- Artery - Aorta5.78
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007188
- GO:0007189
- GO:0007193
- GO:0009612
- GO:0033624
- GO:0034695
- GO:0050728
- GO:2000420
Cellular components
- GO:0005886
- GO:0004957
- GO:0005515
Related records
Trials (767)
- 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
- 24-Hour Vaginal Dinoprostone Pessary Versus Gel for Labour Induction
- 400mcg Sublingual Misoprostol as First Line Treatment
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
- A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
- A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects
- A Comparative Study Between Rectal and Intrauterine Misoprostol Administration in the Reduction of Blood Loss During and After Elective Cesarean Delivery in Low Risk Women
- A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor
- A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion
- A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601
- A Novel Protocol for Labour Induction
- A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks
- A Pilot Study of Priming Before Induction Termination of Pregnancy
- A Prospective Randomized Comparison Trial on the Use of Mifepristone With Sublingual or Buccal Misoprostol for Medical Abortions of Less Than 9 Weeks Gestation
- A Prospective Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location
Drugs (19)
- Alprostadil
- Beraprost
- Cicaprost
- Dinoprost
- Dinoprostone Prostaglandin E2 receptor agonist
- Enprostil
- Epoprostenol
- Evatanepag
- Grapiprant Prostanoid EP4 receptor antagonist
- Iloprost
- Laselipag
- Misoprostol
- Misoprostol acid
- Palupiprant
- Rivenprost Prostanoid EP4 receptor agonist
- Selexipag
- Treprostinil
- Vorbipiprant Prostanoid EP4 receptor antagonist
- Vorbipiprant sodium Prostanoid EP4 receptor antagonist